In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
5-year outcome of acute heart failure in korea: results from the korean acute heart failure registry (KorAHF)
The ESC does not have the copyright for the slides and video of this presentation
1Seoul National University Hospital, Cardiology - Seoul - Korea (Republic of)
2Chungbuk National University Hospital, Cardiology - Cheongju - Korea (Republic of)
3Mediplex Sejong Hospital, Cardiology - Incheon - Korea (Republic of)
On behalf: KorAHF
Background: Heart failure (HF) is associated with high mortality and cost, and even with current advances in medicine, the prevalence of HF is on a steady increase. Purpose: The Korean Acute Heart Failure registry (KorAHF) evaluated the clinical characteristics, treatment, and long-term outcome of patients hospitalized for acute HF. Methods: Patients were prospectively enrolled in 10 university hospitals nationwide from March 2011 to February 2014. A total of 5 625 patients were followed up for up to 5.9 years. Primary outcome was death and readmission due to HF. Total outcome of hospitalized HF patients, along with outcomes in relation to etiology and left ventricular ejection fraction (LVEF) were analyzed. The proportion of patients adhering to guideline-recommended therapies were additionally assessed. Results: The mean age of patients was 68.5 (14.5) years, and 53.2% were male. De novo HF compromised 52.2% of the patients, and 37.6% of total enrolled patients had ischemic etiologies. Acute HF due to ischemic etiologies showed poorer in-hospital, 1-year, and long-term outcomes compared with non-ischemic HF. In relation to LV systolic function, 57.4% of the patients were classified as heart failure with reduced ejection fraction (HFrEF). For these group of patients, there were no differences in survival compared to either heart failure with mid-range or preserved ejection fraction. Regarding oral treatment, guideline-based therapies such as renin-angiotensin system blockers, beta-blockers, and mineralocorticoid receptor blockers were used in 73, 55, and 51% of patients with HFrEF. Conclusion: This registry provides information on the current status and prognosis of acute HF in Korea. Although the proportion of ischemic HF is lower than previous global registries, these patients have worse outcome, suggesting that closer monitoring and treatment is needed.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease